Dr. Reddys Laboratories Ltd.

Dr. Reddy's Laboratories has launched Tadalafil Tablets USP, a therapeutic equivalent generic version of Adcirca (tadalafil) Tablets in the United States (US) market, approved by the U.S. Food and Drug Administration (USFDA).

The Adcirca brand and generic had U.S. sales of approximately $490 million MAT for the most recent twelve months ending in November 2018 according to IMS Health. The company’s Tadalafil Tablets are available in 20 mg with 60 count bottle size.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.